FDA Adverse Event Reporting System (FAERS) Electronic Submissions

Why It Matters

Standardizing on E2B(R3) accelerates safety data flow, reduces compliance risk, and aligns U.S. reporting with global ICH norms, impacting pharma, biotech, and cosmetics firms.

Key Takeaways

• E2B(R3) mandatory for all post‑marketing reports by 2026
• E2B(R2) allowed only until April 1 2026 for legacy use
• SRP offers web‑form entry for entities lacking ESG capability
• MoCRA forces cosmetic SAERs within 15 business days
• IND safety reports must switch to electronic by April 2026

Pulse Analysis

The FDA’s shift to the ICH‑endorsed E2B(R3) standard marks the most significant overhaul of adverse‑event reporting in the United States since the 2014 final rule. Beginning January 16 2024, the agency started accepting electronic post‑marketing individual case safety reports (ICSRs) for drugs and biologics, and on April 1 2024 it opened the same pathway for pre‑marketing IND safety reports. Companies now have a two‑year window to migrate from the legacy E2B(R2) format, with a hard deadline of April 1 2026 after which only E2B(R3) XML submissions will be accepted.

Manufacturers can choose between direct database‑to‑database transmission via the Electronic Submission Gateway (ESG) or the FDA’s Safety Reporting Portal (SRP), which accepts manual web‑form entries. ESG offers the most efficient path for firms with XML capabilities, while SRP provides a low‑tech alternative for smaller companies or those handling cosmetic products that must still use E2B(R2). The dual‑track approach eases the transition but introduces new operational considerations, such as account setup timelines, partner restrictions, and the need to align periodic safety reports (PSRs) with electronic ICSR uploads.

The timing coincides with the Modernization of Cosmetics Regulations Act (MoCRA), which obliges responsible persons to file serious adverse event reports within 15 business days and encourages electronic submission. Aligning cosmetics reporting with the same E2B(R2) framework used for drugs simplifies cross‑sector compliance but also raises expectations for faster data exchange. As global regulators converge on ICH standards, U.S. firms that master E2B(R3) workflows will gain a competitive edge in safety signal detection and regulatory agility, positioning them for smoother product launches and reduced audit findings.